Biotech | September 09, 2021
Eirion Therapeutics mandates HTL Biotechnology to be its exclusive Botulinum API manufacturer.
HTL will build, validate and operate a botulinum manufacturing facility in the US
HTL will build, validate and operate a botulinum manufacturing facility in the US
The batch will be distributed in India through a partner of RDIF and Panacea Biotec - Dr. Reddy's Laboratories
The focus is on wellness and personal care products
The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
The approval allows it to market its products in the country
This therapy may provide the first potential oral treatment for COVID-19, recognizing the global emergency of new SARS-CoV-2 variants
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
Anti-malaria API facility will be operational in 15-18 months
OptumRx to make Pear’s three commercial Prescription Digital Therapeutics accessible to patients with Optum formulary access.
Subscribe To Our Newsletter & Stay Updated
